Professor Georgina Long named as one of world's most highly cited researchers
4 December 2018
Melanoma Institute Australia’s Co-Medical Director Professor Georgina Long has been included in the 2018 Clarivate Analytics Highly Cited Researchers List in recognition of her global leadership in melanoma research and clinical trials.
Professor Long is one of only 12 researchers from The University of Sydney to be listed in the top one percent of researchers in their field. Professor Long was named in the Clinical Medicine category for her extensive work in melanoma research and clinical trials.
‘This is an outstanding achievement and great recognition of the global impact of Professor Long’s research, particularly in clinical trials,’ said fellow MIA Co-Medical Director Professor Richard Scolyer. ‘We are exceptionally proud to have someone of Georgina’s calibre as part of our team which is changing the face of melanoma treatment around the world.’
Now in its 5th year, the Clarivate Analytics Highly Cited Researchers List names the most influential researchers impacting their chosen fields, measured by rate of citation by their peers. Other researchers on the list include one of this year’s Nobel Laureates in Physiology or Medicine, Professor James P. Allison.
The Academic Ranking of World Universities uses the Highly Cited Researchers List to calculate the Highly Cited Score, which contributes to an institutions overall rank. This year, The University of Sydney climbed 15 places to its highest rank so far, due in no small part to research output of Professor Long and the other 11 researchers.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.